OMIA group 2299
Leukaemia, chronic myelomonocytic
The chain reaches the human disease juvenile myelomonocytic leukemia, which Mondo defines as: “A myelodysplastic/myeloproliferative neoplasm of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages. Myelomonocytic proliferation is seen in the bone marrow and the blood. The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement. (WHO, 2001)”
The chain
From the animal disease to the drugs. The page shows what each step found and where the chain stopped. It does not say whether the animal is a model of a human disease.
-
Animal disease
Reached
OMIA records it in 1 species entry marked as a defect.
-
Human disease
Reached
1 Mondo disease.
-
Human gene
Reached
2 human genes.
-
Target evidence
Reached
2 Open Targets associations, with a best score of 0.08.
-
Drugs
Reached
21 ChEMBL drugs, 9 approved. At least one has been tested for this disease.
Natural-model score
How complete and how well supported the chain to each human disease is, out of 100, by stated rules. It does not say that the animal is a validated model of the human disease. How the score works.
56.7 out of 100
| Part | Computed from | Points |
|---|---|---|
| Target evidence | Open Targets score of 0.08 | 2.7 of 35 |
| Drugs | A drug has reached approved for this disease | 25.0 of 25 |
| Ortholog | One to one ortholog | 20.0 of 20 |
| Both routes | One route found this disease | 5.0 of 10 |
| Species | 1 naturally occurring species entry marked as a defect | 4.0 of 10 |
Species
The chain follows only the species entries that OMIA marks as a defect.
| Species | Scientific name | OMIA entry | A defect |
|---|---|---|---|
| dog | Canis lupus familiaris | OMIA:002299-9615 | Yes |
Genes
Each gene OMIA records for a species entry, and the human gene it reaches through Ensembl's orthologs.
| Species | Animal gene | Human gene | Ortholog |
|---|---|---|---|
| dog | ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase NCBI Gene 491292 | ABL1 Ensembl | one to one |
| dog | BCR breakpoint cluster region NCBI Gene 607482 | BCR Ensembl | one to one |
Human diseases
Two routes lead from an OMIA group to a Mondo human disease: OMIA's own Mondo link, and the group's OMIM numbers through Mondo's cross-references.
- OMIA's own Mondo link: OMIA links the group to no Mondo disease.
- OMIA's OMIM numbers: found a disease.
| Mondo disease | Name | Found by |
|---|---|---|
| MONDO:0011908 | juvenile myelomonocytic leukemia A myelodysplastic/myeloproliferative neoplasm of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages. Myelomonocytic proliferation is seen in the bone marrow and the blood. The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement. (WHO, 2001) | OMIA's OMIM numbers |
Target evidence
Each Open Targets association between one of the group's human genes and one of its human diseases, with its overall score and the score for each kind of evidence.
| Human gene | Human disease | Score | Evidence | Kinds of evidence |
|---|---|---|---|---|
| BCR | juvenile myelomonocytic leukemia | 0.08 | 17 | Known drug 0.12 Literature 0.10 |
| ABL1 | juvenile myelomonocytic leukemia | 0.08 | 11 | Known drug 0.12 Literature 0.05 |
Drugs
A drug acts on ABL1 and BCR and has been tested for this disease.
| Drug | Acts on | How | Latest stage | Tested for this disease |
|---|---|---|---|---|
| Imatinib | ABL1 | inhibitor | Approved | Phase 2 for juvenile myelomonocytic leukemia |
| Imatinib | BCR | inhibitor | Approved | Phase 2 for juvenile myelomonocytic leukemia |
| Asciminib | ABL1 | inhibitor | Approved | No |
| Asciminib | BCR | inhibitor | Approved | No |
| Bosutinib | ABL1 | inhibitor | Approved | No |
| Bosutinib | BCR | inhibitor | Approved | No |
| Dasatinib Anhydrous | ABL1 | inhibitor | Approved | No |
| Dasatinib Anhydrous | BCR | inhibitor | Approved | No |
| Flumatinib | ABL1 | inhibitor | Approved | No |
| Nilotinib | ABL1 | inhibitor | Approved | No |
| Nilotinib | BCR | inhibitor | Approved | No |
| Ponatinib | ABL1 | inhibitor | Approved | No |
| Ponatinib | BCR | inhibitor | Approved | No |
| Regorafenib | ABL1 | inhibitor | Approved | No |
| Umbralisib | ABL1 | inhibitor | Approved | No |
| At-9283 | ABL1 | inhibitor | Phase 3 | No |
| Olverembatinib | ABL1 | inhibitor | Phase 3 | No |
| Olverembatinib | BCR | inhibitor | Phase 3 | No |
| Radotinib | ABL1 | inhibitor | Phase 3 | No |
| Radotinib | BCR | inhibitor | Phase 3 | No |
| Ruserontinib | ABL1 | inhibitor | Phase 3 | No |
| Saracatinib | ABL1 | inhibitor | Phase 2/3 | No |
| Bafetinib | ABL1 | inhibitor | Phase 2 | No |
| Vodobatinib | ABL1 | inhibitor | Phase 2 | No |
| Vodobatinib | BCR | inhibitor | Phase 2 | No |
| Rebastinib | ABL1 | inhibitor | Phase 1/2 | No |
| Azd-0424 | ABL1 | inhibitor | Phase 1 | No |
| Kw-2449 | ABL1 | inhibitor | Phase 1 | No |
| Xl-228 | ABL1 | inhibitor | Phase 1 | No |
| Azm-475271 | ABL1 | inhibitor | Unknown | No |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.